Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Kathy Elza-Brown"'
Autor:
Roberto Pili, Michael A. Carducci, Mario A. Eisenberger, Janet R. Walczak, Marianna Zahurak, Samuel R. Denmeade, Kathy Elza-Brown, Eli Rosenbaum, Jill Schmidt, Victoria J. Sinibaldi, Sharyn D. Baker
Publikováno v:
American Journal of Clinical Oncology. 29:395-398
OBJECTIVES In this phase II study, the combination of docetaxel and exisulind (a GMP phosphodiesterase inhibitor) was given to patients with metastatic androgen independent prostate cancer (AIPC) to establish efficacy, assess toxicity, and determine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a42607db6707a01d518d72e362b573fb
https://doi.org/10.1097/01.coc.0000225411.95479.b4
https://doi.org/10.1097/01.coc.0000225411.95479.b4
Autor:
E. Claire Dees, Sharyn D. Baker, Seamus O'Reilly, Michelle A. Rudek, Susan B. Davidson, Cheryl Aylesworth, Kathy Elza-Brown, Michael A. Carducci, Ross C. Donehower
Publikováno v:
Clinical Cancer Research. 11:664-671
Purpose: To define the maximum tolerated dose and the dose-limiting toxicity of the kinase modulator UCN-01 administered as a short (1-3 hours) infusion to patients with refractory solid tumors and to evaluate the pharmacokinetics of this novel agent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bb15a77f3bdad84685183e57a9b2a739
https://doi.org/10.1158/1078-0432.664.11.2
https://doi.org/10.1158/1078-0432.664.11.2
A Phase I and Pharmacologic Study of Pyrazoloacridine and Cisplatin in Patients with Advanced Cancer
Autor:
Kathy Elza-Brown, Eric K. Rowinsky, Ross C. Donehower, Dennis A. Noe, Alex A. Adjei, E. Claire Dees, Seamus O’Reilly
Publikováno v:
Investigational New Drugs. 21:75-84
Pyrazoloacridine (PZA, NSC366140, PD115934) is an acridine derivative currently undergoing clinical evaluation. In preclinical testing, PZA has shown selectivity for solid tumor cell lines, activity in hypoxic, noncycling, and multidrug-resistant cel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c7c964797fb8a1ef679890cf85b8560
https://doi.org/10.1023/a:1022924511602
https://doi.org/10.1023/a:1022924511602
Autor:
E Claire, Dees, Sharyn D, Baker, Seamus, O'Reilly, Michelle A, Rudek, Susan B, Davidson, Cheryl, Aylesworth, Kathy, Elza-Brown, Michael A, Carducci, Ross C, Donehower
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 11(2 Pt 1)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ba268197f548a6a4a8883428d04b15f4
https://pubmed.ncbi.nlm.nih.gov/15701854
https://pubmed.ncbi.nlm.nih.gov/15701854
Autor:
Kathy Elza-Brown, V. J. Sinibaldi, S. Moore-Cooper, Elizabeth Garrett-Mayer, Roberto Pili, Mario A. Eisenberger, Janet R. Walczak, Eli Rosenbaum, Samuel R. Denmeade, Michael A. Carducci
Publikováno v:
Journal of Clinical Oncology. 24:14612-14612
14612 Background: Imatinib mesylate (Gleevec, G) is a potent inhibitor of the tyrosine kinases and other signaling mediated events. Preclinical models suggest that G inhibits platelet derived growth factor (PDGF) and stem cell factor (SCF) which are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::07a7e3f0d76f0b97ee965e7b4369c1e6
https://doi.org/10.1200/jco.2006.24.18_suppl.14612
https://doi.org/10.1200/jco.2006.24.18_suppl.14612
Autor:
Janet R. Walczak, Eli Rosenbaum, Michael A. Carducci, Marianna Zahurak, Roberto Pili, J. Stewart, Sharyn D. Baker, Samuel R. Denmeade, V. J. Sinibaldi, Kathy Elza-Brown
Publikováno v:
Journal of Clinical Oncology. 23:4758-4758
4758 Background: Preclinical data suggested synergistic anti-tumor activity with the combination of D + E in AIPC. E is a GMP phosphodiesterase inhibitor administered orally. We designed a trial evaluating tumor response (↓PSA ≥50% lasting ≥4 w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f3c480d8f70011bddb0edc56c05f6d56
https://doi.org/10.1200/jco.2005.23.16_suppl.4758
https://doi.org/10.1200/jco.2005.23.16_suppl.4758
Autor:
M.A. Rudeck, Sharyn D. Baker, W.T. Purcell, Kathy Elza-Brown, Janet Dancey, Ross C. Donehower, Yelena Zabelina, T. Rogers, Antonio Jimeno, Michael A. Carducci
Publikováno v:
European Journal of Cancer Supplements. 2:129
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::459af34cb3aa2c25d62e1f83e13a5c8f
https://doi.org/10.1016/s1359-6349(04)80438-5
https://doi.org/10.1016/s1359-6349(04)80438-5